Why the study?
To summarize available real-world evidence and discuss the relevance and importance of idarucizumab reversal in dabigatran-treated acute stroke patients in everyday clinical practice.
Does idarucizumab improve clinical outcomes and safely reverse anticoagulation in dabigatran-treated patients with acute stroke?
Does idarucizumab improve clinical outcomes and safely reverse anticoagulation in dabigatran-treated patients with acute stroke?
This narrative review supports the routine clinical use of idarucizumab as a first-line reversal agent for dabigatran-treated patients presenting with acute ischemic stroke who are eligible for thrombolysis, or those with intracranial hemorrhage.
Supports idarucizumab for dabigatran reversal in acute stroke; extends real-world data but leaves open randomized outcome trials.
Idarucizumab is an antibody fragment specific for the immediate reversal of dabigatran anticoagulation effects. The use of idarucizumab is approved for dabigatran-treated patients suffering from life-threatening or uncontrolled bleeding and those in need of urgent surgery or invasive procedures. Data from randomized controlled clinical trials and real-world experience provide reassuring evidence about the efficacy and safety of idarucizmab use in patients with acute stroke. In this narrative review, we summarize the available real-world evidence and discuss the relevance and importance of idarucizumab treatment in acute stroke patients in everyday clinical practice. In addition, we also discuss special issues like prothrombin complex concentrate application as an alternative to idarucizumab, its application before endovascular therapy, sensitivity of thrombi to lysis, and necessary laboratory examinations.
No takes yet. Share an insight, caveat, or question.
Frol et al. (2024) conducted a review in Acute ischemic stroke and intracranial hemorrhage in dabigatran-treated patients. Idarucizumab was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: